Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 68 publications
A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2.
Journal: Cancer research communications
Published: December 16, 2024
Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration.
Journal: Molecular carcinogenesis
Published: April 23, 2024
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Journal: Nature medicine
Published: April 23, 2024
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 01, 2024
Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors.
Journal: Investigational new drugs
Published: December 07, 2022
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers.
Journal: NPJ precision oncology
Published: November 07, 2022
Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer.
Journal: Journal of hematology & oncology
Published: May 28, 2021
Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer.
Journal: Cancer cell
Published: September 08, 2020
Bromodomain inhibitors a decade later: a promise unfulfilled?
Journal: British journal of cancer
Published: July 27, 2020
Last Updated: 09/26/2026